TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3139429
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine and ranitidine (standard and modified dosage)
Study: 10901337
Drug: Benzodiazepine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine therapy for GAD (diazepam and lorazepam)
Study: 8627060
Drug: High-dose zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose zidovudine (180 mg/m2/dose)
Study: 8627060
Drug: Low-dose zidovudine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose zidovudine (90 mg/m2/dose)
Study: 1418392
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg/day) and nimesulide (200 mg/day)
Study: 1418392
Drug: Terfenadine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (120 mg/day) and placebo
Study: 6504947
Drug: Once-daily dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Study: 6504947
Drug: Twice-daily dosage
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosage of hydrochlorothiazide (25 mg), amiloride (2.5 mg), and timolol (10 mg)
Study: 6504947
Drug: Both once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both once-daily and twice-daily regimens
Study: 31798891
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment for 12 weeks
Study: 29432286
Drug: Extended-release carbidopa-levodopa
Normalized name: carbidopa / levodopa Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release carbidopa-levodopa (ER CD-LD)
Study: 16208597
Drug: Valdecoxib (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (maximum single dose: 20 mg; cumulative dose: 35 mg)
Study: 11895538
Drug: DOXI (subgingival
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOXI (subgingival application of 15% doxycycline gel)
Study: 31658543
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment (0.2 IU·kg(‐1)·d(‐1) subcutaneously for 7 days)
Study: 31658543
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (anti-shock, anti-infection, and wound caring therapies)
Study: 25428785
Drug: Xylitol gummy
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol gummy bears (7.8 g/day)
Study: 25428785
Drug: Placebo gummy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gummy bears (inulin fiber 20 g/day)
Study: 19563189
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Source Point and Back‐Shu Point group
Study: 9564118
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (mean initial dose: 69.5 micrograms fentanyl/hr; mean final dose: 167.7 micrograms fentanyl/hr)
Study: 29652246
Drug: Prolonged-release metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release metformin (500 mg)
Study: 26968357
Drug: Rigosertib 1800
Normalized name: Rigosertib
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week
Study: 20022282
Drug: Estradiol antagonist
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol antagonist (4 mg/day starting on the 25th day of the previous cycle)
Study: 20022282
Drug: Estradiol antagonist
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol antagonist
Study: 20022282
Drug: Long agonist
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long agonist (Decapeptyl 0.1 mg starting on the 20th day of the previous cycle)
Study: 18506026
Drug: Postoperative cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin-based chemotherapy
Study: 18506026
Drug: Postoperative cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin-based chemotherapy with vinorelbine
Study: 18506026
Drug: Postoperative cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin-based chemotherapy with etoposide or vinca alkaloid
Study: 18506026
Drug: Postoperative cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin-based chemotherapy with other drugs
Study: 12856812
Drug: Biological background
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological background knowledge
Study: 12856812
Drug: Physiological theory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological theory of drug action curriculum
Study: 10699223
Drug: Sleep enhancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep enhancing medication use
Study: 8380243
Drug: Ganciclovir (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (6 mg/kg once per day after transplant)
Study: 2879752
Drug: lormetazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: lormetazepam (10 drops twice daily for 4 weeks)
Study: 2879752
Drug: diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (10 drops twice daily for 4 weeks)
Study: 20832963
Drug: Ticagrelor loading
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor loading dose
Study: 29569476
Drug: Unilateral lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral lateral rectus resection under topical anesthesia
Study: 22879423
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of lutein and 2 mg of zeaxanthin per day (intervention group)
Study: 18164454
Drug: Facet injections
Normalized name: potassium acetate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facet injections
Study: 12745507
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch with culturally sensitive self-help quitting materials
Study: 12745507
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch with standard self-help quitting materials
Study: 10365496
Drug: Intravenous Sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Sedation (IVS)
Study: 6391072
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol combined with 2% pilocarpine
Study: 6391072
Drug: 0.5% topical
Normalized name: Carac 0.5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% topical timolol combined with 2% pilocarpine
Study: 30344165
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and fluorouracil (TF) concurrent with radiotherapy
Study: 30344165
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and cisplatin (TP) concurrent with radiotherapy
Study: 30344165
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and carboplatin (TC) concurrent with radiotherapy
Study: 27770771
Drug: Ambrisentan (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (5 mg once daily for 12 weeks, with dose titration to 10 mg allowed)
Study: 23158730
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (omeprazole 0.8 - 1.0 mg/(kg·d) + amoxicillin-clavulanate 50 mg/(kg·d) for 5 days, followed by omeprazole 0.8 - 1.0 mg/(kg·d), clarithromycin 20 mg/(kg·d), and metronidazole 20 mg/(kg·d) for 5 days)
Study: 23158730
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 7 days)
Study: 23158730
Drug: 10-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 10 days)
Study: 23158730
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 14 days)
Study: 18496884
Drug: Cognitive Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Training (CT) - 10 sessions of 2 hours, twice weekly
Study: 18496884
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation (CS) - 8 sessions of 1.5 hours, once weekly
Study: 9787945
Drug: Neoral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral formulation (1:1 dose-ratio conversion)
Study: 9787945
Drug: Neoral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral formulation (0.75 dose-ratio conversion)
Study: 9787945
Drug: Neoral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral formulation (1:1 and 0.75 dose-ratio conversion)
Study: 9787945
Drug: Limited sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Limited sampling strategy (three blood samples post-dosing of Neoral formulation)
Study: 9787945
Drug: Neoral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral formulation
Study: 7707126
Drug: Pentostatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostatin (4 mg/m2 intravenously every 2 weeks)
Study: 27650383
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of superiority and non-inferiority aims for the endpoints
Study: 23328339
Drug: Psychoeducational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational treatment (9 sessions of 2 hours each: 5 sessions of education about the illness + 4 sessions of autogenic relaxation)
Study: 23328339
Drug: Psychoeducational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational treatment
Study: 20683595
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg every 3 weeks for six cycles
Study: 20683595
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg every 3 weeks for six cycles
Study: 10227503
Drug: Sublingual 1-hyoscyamine
Normalized name: hyoscyamine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 1-hyoscyamine sulfate
Study: 9772597
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine combined with cord blood infusion
Study: 9772597
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood infusion solely
Study: 1832701
Drug: 3 capsules
Normalized name: Xymogen Medcaps T3 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 capsules of fish oil daily for 6 months
Study: 1832701
Drug: 6 capsules
Normalized name: TOBI Podhaler Weekly Kit, including 56 capsules (7 Blister Cards of 8 Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 capsules of fish oil daily for 6 months
Study: 1832701
Drug: 9 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 capsules of fish oil daily for 6 months
Study: 1832701
Drug: 12 capsules
Normalized name: nylon 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 capsules of fish oil daily for 6 months
Study: 1832701
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses except the lowest
Study: 1832701
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose (12 capsules)
Study: 1832701
Drug: Two middle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two middle doses (6 and 9 capsules)
Study: 6227208
Drug: 24 hour
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hour urinary noradrenaline excretion (in upper blood pressure range)
Study: 6227208
Drug: Plasma insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma insulin (in intermediate blood pressure range)
Study: 29962429
Drug: PYC chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PYC chewing gum (2.5 mg per piece, 2 pieces, 6 times daily for 15 min)
Study: 21853290
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tolvaptan with 240 mL of reconstituted grapefruit juice
Study: 21853290
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tolvaptan with 240 mL of water
Study: 11877767
Drug: High-dose myeloablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8 at doses of 261-495 mCi, with a protein dose of 2.5 mg/kg (or 10 mg/kg for one patient with splenomegaly).
Study: 11877767
Drug: High-dose myeloablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8.
Study: 10223779
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of lanreotide
Study: 2367653
Drug: Blood patch
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood patch technique (group A)
Study: 2367653
Drug: No blood
Normalized name: VivaGuard Ino Blood Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: No blood patch (group B)
Study: 30797042
Drug: Buprenorphine Bridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine Bridge Treatment (BBT)
Study: 20589922
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg paliperidone ER OROS
Study: 20589922
Drug: 9 mg
Normalized name: fiber 469 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg paliperidone ER OROS
Study: 17379842
Drug: Fluvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20 mg/d)
Study: 17379842
Drug: Colestimide (3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestimide (3000 mg/d)
Study: 12193911
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (1 to 4 mU/min) and placebo intravaginal misoprostol
Study: 12193911
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (50 microg, repeated at 4 hourly intervals if <3 uterine contractions per 10 minutes)
Study: 8520442
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day for 7 days)
Study: 2361796
Drug: Topical aluminium
Normalized name: Aluminium
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical aluminium chloride hexahydrate 20% W/W ethanol (ACH) applied daily for 4 weeks
Study: 415471
Drug: Sulpiride 50
Normalized name: sulpiride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride 50 mg injection
Study: 27696656
Drug: Triple intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple intrathecal therapy without cranial radiation (CrRT)
Study: 25680375
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (specific agents not detailed)
Study: 23640544
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) delivered by a psychologist plus treatment as usual (education, reassurance, and symptom management strategies)
Study: 23640544
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (education, reassurance, and symptom management strategies)
Study: 21533329
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural treatment
Study: 15090770
Drug: GW433908/ritonavir (908/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908/ritonavir (908/r) 1400 mg/200 mg, once daily (q.d.)
Study: 15090770
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg, twice daily (b.i.d.)
Study: 11274623
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (120 mg of bismuth subcitrate, 500 mg of tetracycline, and 400 mg of metronidazole, all given four times daily for one week)
Study: 11274623
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for six months)
Study: 9636912
Drug: Heparin-coated circuits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuits (n = 11)
Study: 28503741
Drug: Autologous platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet-rich plasma injection
Study: 26301701
Drug: brexpiprazole 2
Normalized name: brexpiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 2 mg/d
Study: 23178320
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine (LN, 0.4 mg/g)
Study: 23178320
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine (HN, 11.4-12.8 mg/g)
Study: 23178320
Drug: Intermediate nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate nicotine (IN, 5.7-5.8 mg/g)
Study: 18297436
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment schedule (three treatment sessions per week for the first 2 weeks)
Study: 18297436
Drug: Original treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original treatment schedule (weekly treatment)
Study: 16296399
Drug: Microalgae oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microalgae oil (0.94 g DHA/d)
Study: 15289837
Drug: CDDP (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 1 and 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 2‐5 (Group A)
Study: 15289837
Drug: 5‐FU (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (700 mg/m(2)) as a continuous intravenous infusion on days 1‐4, followed by CDDP (80 mg/m(2)) as a continuous 2‐h intravenous infusion on day 5 (Group B)
Study: 11762807
Drug: Oral vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vinorelbine at 60 mg/m2/week for the first three administrations, then increased to 80 mg/m2/week
Study: 11762807
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) vinorelbine at 30 mg/m2/week
Study: 8996153
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (CT) plus radiotherapy (RT): cisplatin 75 mg/m2 on day 1 and fluorouracil (5FU) 1,000 mg/m2/d on days 1 to 4 every 4 weeks with RT and every 3 weeks post‐RT.
Study: 8996153
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy (CT) plus radiotherapy (RT): additional patients treated with the same combined therapy.
Study: 8435253
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 20 mg
Study: 3315513
Drug: Insulin bolus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin bolus at 2300 h (2.1 +/- 0.2 U)
Study: 3315513
Drug: Insulin bolus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin bolus at 0100 h (after reactivating the pump at 1.05 +/- 0.11 U/h)
Study: 29596158
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy (SMT) combined with exercise therapy (ET)
Study: 29596158
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) alone
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid alone
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Metformin 500 mg po bid
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Nateglinide 60 mg po tid
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Vildagliptin 50 mg po bid
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Liraglutide 0.6 mg sc qd
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Nateglinide
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Metformin
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Liraglutide
Study: 24461109
Drug: Pasireotide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 600 μg sc bid + Vildagliptin
Study: 22648092
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (330 ml/day for four weeks)
Study: 22648092
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink (330 ml/day for four weeks)
Study: 20099369
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ebastine plus 120 mg of pseudoephedrine complex
Study: 10406065
Drug: Adjunctive pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive pharmacotherapy with potent antiplatelet agents